Fmr LLC Precigen, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Precigen, Inc. stock. As of the latest transaction made, Fmr LLC holds 273,171 shares of PGEN stock, worth $292,292. This represents 0.0% of its overall portfolio holdings.

Number of Shares

273,171

Previous 255,635 6.86%

Holding current value

$292,292

Previous $370,000 16.49%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.27 - $1.75 $22,270 - $30,688	17,536 Added 6.86%	273,171 $431,000
Q1 2024 May 13, 2024	SELL	$1.21 - $1.75 $340 - $491	-281 Reduced 0.11%	255,635 $370,000
Q4 2023 Feb 13, 2024	SELL	$0.89 - $1.41 $51,129 - $81,003	-57,449 Reduced 18.33%	255,916 $342,000
Q3 2023 Nov 13, 2023	BUY	$1.08 - $1.85 $120,813 - $206,948	111,864 Added 55.52%	313,365 $444,000
Q2 2023 Aug 11, 2023	BUY	$0.96 - $1.4 $2,028 - $2,958	2,113 Added 1.06%	201,501 $231,000
Q1 2023 May 11, 2023	BUY	$0.88 - $2.19 $14 - $35	16 Added 0.01%	199,388 $211,000
Q4 2022 Feb 13, 2023	SELL	$1.27 - $2.26 $2,524 - $4,492	-1,988 Reduced 0.99%	199,372 $303,000
Q3 2022 Nov 10, 2022	BUY	$1.41 - $2.79 $3,840 - $7,599	2,724 Added 1.37%	201,360 $427,000
Q2 2022 Aug 12, 2022	SELL	$1.15 - $2.53 $3,646 - $8,022	-3,171 Reduced 1.57%	198,636 $266,000
Q1 2022 May 13, 2022	BUY	$1.91 - $3.98 $381,799 - $795,582	199,895 Added 10454.76%	201,807 $426,000
Q4 2021 Feb 14, 2022	SELL	$3.53 - $5.5 $31 - $49	-9 Reduced 0.47%	1,912 $7,000
Q3 2021 Nov 15, 2021	BUY	$4.99 - $6.55 $284 - $373	57 Added 3.06%	1,921 $9,000
Q2 2021 Aug 13, 2021	BUY	$6.24 - $8.22 $11,631 - $15,322	1,864 New	1,864 $12,000

Others Institutions Holding PGEN

# of Institutions

143

Shares Held

144M

Call Options Held

292K

Put Options Held

53.8K

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $223M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account